Cargando…
Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (M(pro)), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral r...
Autores principales: | Jain, Mamta K., De Lemos, James A., McGuire, Darren K., Ayers, Colby., Eitson, Jennifer L., Sanchez, Claudia L., Kamel, Dena, Meisner, Jessica A., Thomas, Emilia V., Hegde, Anita A., Mocherla, Satish, Strebe, Joslyn K., Li, Xilong, Williams, Noelle S., Xing, Chao, Ahmed, Mahmoud S., Wang, Ping, Sadek, Hesham A., Schoggins, John W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561237/ https://www.ncbi.nlm.nih.gov/pubmed/36249792 http://dx.doi.org/10.3389/fphar.2022.1020123 |
Ejemplares similares
-
525. Atovaquone for Treatment of COVID-19 (Ataq COVID-19) Trial
por: Jain, Mamta K, et al.
Publicado: (2021) -
Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow‐up
por: Lau, Abby A., et al.
Publicado: (2022) -
Antimalarial pharmacology and therapeutics of atovaquone
por: Nixon, Gemma L., et al.
Publicado: (2013) -
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Bakshi, Rahul P., et al.
Publicado: (2018) -
Efficacy of Azithromycin and Compounded Atovaquone for Treatment of Babesia gibsoni in Dogs
por: Kirk, S.K., et al.
Publicado: (2017)